IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

A REVIEW ON DRUG KETOROLAC

Bhongale Anisha, Kadam Pratiksha

Pragati Pansare, Tejashree Sapre

B. Pharmacy Final Year Students, Sarsam College of Pharmacy, Palshiwadi.

Dr. Babasaheb Ambedkar Technological University, Lonere, Maharashtra, India

Guide: Asst. Prof. Pratik B. Lakade.

M. Pharm. Chemistry

ABSTRACT:

Ketorolac tromethamine, a potent nonsteroidal anti-inflammatory medicine (NSAID), has been considerably used for the treatment of moderate to severe pain. The original conflation of ketorolac involves a multistep process that requires harsh response conditions and produces a significant quantum of waste. Over the times, colourful synthetic styles have been developed to ameliorate the effectiveness and environmental knowledge of ketorolac product. This review paper provides a comprehensive overview of the different synthetic approaches for ketorolac. It discusses the advantages and disadvantages of each system and highlights the recent advancements in the field. The paper also accentuates the significance of green chemistry principles in the conflation of ketorolac and other Medicinals. The review concludes that the conflation of ketorolac has experienced significant advancements in recent times. still, there's still a need for farther development of more effective, environmentally friendly, and cost-effective synthetic styles.

KEYWORDS*:* hydrogels, swelling study, drug release, in-vivo study.

INTRODUCTION:

Ketorolac is a drug used in the operation and treatment of acute moderate to severe pain. It's in the nonsteroidal anti-inflammatory medicine class. This exertion outlines the suggestions, conduct, and contraindications for ketorolac as a precious agent in treating acute pain. It'll also punctuate the medium of action, adverse event profile, and other crucial factors (e.g., contraindications, monitoring, toxin) material for members of the interprofessional platoon in treating cases with acute moderate to severe pain. Ketorolac is a pyrazoline carboxylic acid outgrowth, structurally and pharmacologically related to tolmetin, zomepirac, and indomethacin. The trometamol swab of ketorolac enhances its solubility and allows parenteral administration.

Views on the safety of ketorolac in EC medicine nonsupervisory authorities are clashing. [1,2] still, the threat of adverse responses is advanced when ketorolac is used in advanced boluses, in senior subjects, and for further than 5 days. [3]

Other information on the benefit- to- detriment balance of parenteral ketorolac tromethamine as a postoperative analgesic has been handed by three studies. [4] The overall threat of gastrointestinal and operative point bleeding and acute renal insufficiency associated with parenteral ketorolac and a parenteral opioid were fairly small.

The most generally reported symptoms are doziness, headache, dizziness, nausea, dyspepsia, and abdominal pain; oedema, hyperkalaemia, diarrhoea, sweating, tone- limiting gasping, and itching have also been reported sometimes [4 – 9].

A nonsupervisory review of ketorolac in numerous countries led to modification of the marker, lozenge recommendations, and defining practices. Ketorolac should be limited in lozenge and duration; in senior cases it should presumably not be used at all. adding the lozenge of ketorolac beyond the marker recommendations (60 – 120 mg/ day for an outside of 2 – 5 days) won't give better efficacity but will increase the threat of serious adverse responses [5].

STRUCTURE OF KETOROLAC:



Ketorolac, with the chemical formula C15H13NO3, is a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat moderate to severe pain. It is available in both oral and injectable forms. Chemically, ketorolac is a racemate, meaning that it is a mixture of two mirror-image isomers, (R)-ketorolac and (S)-ketorolac. [6]

The structure of ketorolac can be divided into three main parts:

A benzene ring: This ring is the core of the molecule and provides the aromatic character.

A pyrrolizine ring: This ring is fused to the benzene ring and contains a nitrogen atom.

A carboxylic acid group: This group is attached to the pyrrolizine ring and gives ketorolac its acidic properties.

The two enantiomers of ketorolac have different pharmacological properties. The (S)-enantiomer is a potent inhibitor of cyclooxygenase (COX), an enzyme that is involved in the production of prostaglandins, which are molecules that cause pain and inflammation. The (R)-enantiomer is less potent as a COX inhibitor, but it is also an analgesic, meaning that it can relieve pain.[7]

Synthetic Methods

Ketorolac is synthesized in a multistep process that involves the following steps:

Preparation of the pyrrolizine ring: This step involves the condensation of two molecules of malononitrile with an α-keto acid.

Benzoylation of the pyrrolizine ring: This step involves the reaction of the pyrrolizine ring with benzoyl chloride.

Resolution of the racemate: This step involves the separation of the (R)- and (S)-enantiomers of ketorolac. [8]

PHYSIOCHEMICAL PROPERTIES:

S. NO.	PHYSICAL AND CHEMICAL PROPERTIES	
1	Molecular weight	255.27 g/mol
2	Physical appearance	Solid
3	Melting point	162-165°C
4	Solubility	Trimethamine salt solubility is 200 g/L
5	Octanol/water partition coefficient	2.1
6	Presence of ring	Pyrrolizine, phenyl
7	Number of chiral centers	1

PHARMACOLOGY OF KETORALAC:

Ketorolac is an NSAID, which has its action through the inhibition of prostaglandin synthesis. As an NSAID, ketorolac inhibits the action of the cyclooxygenase enzymes (COX-1 and COX-2), which metabolise arachidonic acid to prostaglandins and thromboxane A2. NSAIDs are therefore considered to be highly effective for prostaglandin-mediated pathologies causing pain and inflammation including trauma (Curtis and Morrell, 2006; Bartkus, 2011; Gadsden, 2012). [9] Ketorolac has also been shown both clinically and in vitro to inhibit stretch-induced ureteral contractility associated with renal colic when passing kidney stones, making it particularly useful for colicky pain (Wood et al, 2000; Wen et al, 2008). [10] Ketorolac can be administered by various routes, but the IM and IV routes are most common. These routes would produce a more rapid rise in serum concentration and bioavailability compared to the oral route. This would be beneficial in the acute pain setting, and would also be useful for patients destined for emergency surgery who need to be kept nil by mouth. [11]

MECHANISM OF ACTION OF KETOROLAC:





Ketorolac is a Non-steroidal anti-inflammatory medicine(NSAID) and has antipyretic, analgesic anti-inflammatory parcels. [12] It's indicated for short term operation of acute pain that requires the class of pain operation offered by opioids.[13] Clinicians may choose to initiate ketorolac to manage post-operative pain, spinal and soft towel pain, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, menstrual diseases and headaches among other affections.[14] Anyhow of the etiology of pain, cases should use the smallest possible cure, and avoid using ketorolac for an extended period of time(immaculately ≤ 5 days).[15] A benefit of choosing ketorolac over other anesthetics with analogous energy is that that there doesn't appear to be a threat of dependence or forbearance with ketorolac use.

SYNTHESIS OF KETOROLAC:

(STEP I): Pyrrole is converted into pyrrole Grignard reagent by the reaction of pyrrole with methyl magnesium chloride.

(STEP 2): Pyrrole Grignard reagent so formed is contacted with dihalobutanamide to form N-alkyl-N-aryl-4-chloro-2-(2-pyrrolyl) butanamide.

(STEP 3): The pyrrolyl butanamide is cyclized to form N-alkyl-N-aryl-2,3-dihydro-1H-pyrrolizine-1-carboxamide.

(STEP 4): The above formed compound undergoes 5-aroylation method to form N-alkyl-N-aryl-5-benzoyl-2,3-dihydro-1H pyrrolizine-1-carboxamides.

(STEP 5): The ketorolac-amide so formed is converted to ketorolac through hydrolysis using strong base in an alkanol. [16]



PRINCIPLES OF INJECTION THERAPY:

Ketorolac is a nonsteroidal anti-inflammatory medicine (NSAID) that inhibits the seditious cyclooxygenase and lipoxygenase enzyme systems, and the conflation of prostaglandins and leukotrienes. Ketorolac provides a reasonable volition to corticosteroids and HA because it has smaller side goods than corticosteroid, has a briskly onset of action than HA, and is more provident than both HA and corticosteroid.

In cases with knee and first carpometacarpal common osteoarthritis, the addition of ketorolac to HA injection handed more rapid-fire onset of pain relief without any added complications when compared with HA alone. In addition, when compared head- to- head with corticosteroid in cases with knee and hipsterism osteoarthritis, ketorolac handed analogous advancements in pain and function for over to 6 months. Ketorolac has also been shown to be safe and more effective than corticosteroids in the treatment of shoulder smash and tenacious capsulitis.

PHARMACOKINETIC PARAMETER:

Ketorolac is a new chiral nonsteroidal anti-inflammatory medicine (NSAID) which is retailed for analgesia as the racemate. The medicine is administered as the water answerable tromethamine swab and is available in tablets or as an intramuscular injection. The immersion of ketorolac is rapid-fire, C-max being attained between 20 to 60 min. Its oral bioavailability is estimated to range from 80 to 100. The medicine is considerably bound (> 99) to tube proteins and has a volume of distribution (0.1 to0.3 L/ kg) similar with those of other NSAIDs. [17,18] Only small attention of ketorolac are sensible in umbilical tone blood after administration to women in labour. The elimination half- life is between 4 and 6h and is moderate in comparison with other NSAIDs. The area under the tube attention- time wind of ketorolac is commensurable to the cure after intramuscular administration of remedial boluses to youthful healthy levies. [19]

Ketorolac is considerably metabolised through glucuronidation and oxidation; little if any medicine is excluded unchanged. utmost of the cure of ketorolac is recovered in the urine as conjugated medicine. Although ketorolac is excreted into the bone milk, the quantum of medicine transferred comprises only a small bit of the motherly exposure. Little stereoselectivity was present in the pharmacokinetics of ketorolac in a healthy levy entering single intravenous or oral boluses. The senior parade reduced concurrence of the medicine. Renal insufficiency appears to beget an accumulation of ketorolac in tube, although hepatic complaint may not affect the pharmacokinetics [20]

ADMINISTRATION:

The administration of ketorolac can be done via oral, nasal spray, IV, or IM routes. The oral interpretation should be administered only following IV or IM ketorolac. Ketorolac administration shouldn't be for longer than five days, given an increased threat of cardiac thrombotic events, renal failure, peptic ulcers, and increased threat of bleeding beyond this point. [21]

DOSAGE FORMULATION:

Ketorolac tromethamine IV injection solution: 15 mg/mL; 30 mg/mL

Ketorolac tromethamine IM injection solution: 60 mg/2 mL

Oral tablets: 10 mg

Adult Dosing

IV and IM dosing for adults are recommended at 30 mg single dose or 30 mg every 6 hours, not exceeding 120 mg in 24 hours.

The recommended oral dosing in adults is a 20 mg single dose after IV or IM therapy, then 10 mg every 4 to 6 hours, not exceeding 40 mg in 24 hours.

Half-life: 5.6 hours for a single 30 mg IM or single 10 mg oral dose

Paediatric Dosing (off-label for acute moderate to severe pain; ketorolac has no approval for use under the age of 17)

Less than two years

Not recommended

2 to 16 years

Single-dose: 0.5 mg/kg IV/IM once; not to exceed 15 mg

Multiple-dose: 0.5 mg/kg IV/IM q6h; not to exceed 5 days

Over 16 years, less than 50 kg

IV: 15 mg in a single dose or 15 mg every 6 hours; do not exceed 60 mg/day

IM: 30 mg in a single dose or 15 mg every 6 hours; do not exceed 60 mg/day

PO: 10 mg once after IV/IM therapy, then 10mg every 6 hours; do not exceed 40 mg/day

Over 16 years, greater than 50 kg

Adult dosing as described above.

TOXICITY

High quantities or prolonged use of ketorolac can lead to hepatotoxicity and renal toxicity. In addition, ketorolac can cause multiple skin issues, such as toxic epidermal necrolysis. In combination with lithium, it increases the risk of lithium toxicity, given that lithium also gets excreted renally. [22]

Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) used to treat moderate to severe pain, such as pain after surgery or injury. It is available in various formulations, including oral tablets, injectable solutions, and topical gels. [23]

General Toxicity Profile

Ketorolac is generally well-tolerated when used as directed. However, like all NSAIDs, it can cause side effects, some of which can be serious. The most common side effects of ketorolac include:

Stomach upset, nausea, and vomiting

Diarrhoea

Heartburn

Dizziness

Headache

Drowsiness

Dose-Related Toxicity

The risk of side effects increases with higher doses of ketorolac. This is particularly true for the most serious side effects, such as:

Stomach bleeding

Kidney problems

Liver problems

Prolonged Use Toxicity

Prolonged use of ketorolac, even at low doses, can increase the risk of serious side effects. For this reason, ketorolac is typically only recommended for short-term use, usually less than 5 days.

Toxicity of Different Formulations

The toxicity of ketorolac can vary depending on the formulation used.

Oral Tablets: Oral tablets are the most common formulation of ketorolac. They are generally well-tolerated, but they can cause stomach upset and bleeding.

Injectable Solutions: Injectable solutions of ketorolac are typically used for short-term pain relief, such as after surgery. They can cause some of the same side effects as oral tablets, but they are also associated with an increased risk of allergic reactions and anaphylaxis.

Topical Gels: Topical gels of ketorolac are used to treat pain from arthritis and other musculoskeletal conditions. They are generally less likely to cause systemic side effects than oral tablets or injectable solutions. However, they can cause skin irritation.

Precautions

1.Ketorolac should be used with caution in people with certain medical conditions, such as:

2.Stomach ulcers or bleeding

3.Kidney or liver problems

4.Asthma or other breathing problems

5.Heart disease

6.Stroke

7.High blood pressure

8.Ketorolac should also be avoided in pregnant women and women who are breastfeeding.

9.Ketorolac is an effective pain reliever, but it can cause side effects, some of which can be serious. It is important to be aware of the potential risks and benefits of ketorolac before taking it. Talk to your doctor about whether ketorolac is right for you.



ADVERSE EFFECTS:

Adverse effects of ketorolac increase significantly when used in higher doses, for durations over five days, and in patients who are over 75 years old. Like other NSAIDs, ketorolac shows correlations with significant gastrointestinal (GI), renal, and cardiovascular risks. [24] In the GI system, it can cause peptic ulcers and/or perforations of the stomach or intestines. In an extensive pooled data set, all NSAIDs, including COX2 inhibitors, were shown to increase the relative risk for peptic ulcers, with ketorolac having the highest RR at 11.5.[25] Because of its antiplatelet properties, ketorolac increases the risk of GI bleeding. It also increases postoperative bleeding risk when compared with opioids. [26]

Ketorolac can cause an increased risk of cardiovascular thrombotic events, myocardial infarctions, **Common side effects of ketorolac include:**

and haemorrhagic stroke. Heart failure is a significant risk factor for the adverse effects of NSAIDs. A large case-controlled study spanning multiple European countries tested the risk of heart failure for 27 different NSAIDs, including 92,163 hospital admissions for heart failure and 824,6403 control patients. Seven NSAIDs were shown to increase the risk of heart failure, with ketorolac having the highest odds ratio of 1.83 vs. the lowest odds ratio of 1.16 for naproxen. [27] Lastly, ketorolac can cause renal damage and failure. In a population-based case-controlled study conducted in southern Italy, ketorolac was shown to have the highest odds ratio of increasing the cumulative risk for chronic kidney disease (OR 2.58 after 0 to 90-day use vs. 1.08 for any NSAID). [28]

SIDE EFFECTS:

Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat pain and inflammation. It is available in tablets, injections, and eye drops. Ketorolac can cause a number of side effects, some of which are more common than others. [29]

1.Nausea and vomiting

2.Diarrhea

3.Constipation

4.Indigestions

5.Headache

6.Dizziness

7.Drowsiness

8.Rash

9.Less common side effects of ketorolac include:

10.Stomach ulcers and bleeding

11.Kidney problems

12.Liver problems

13.Heart attack

14.Stroke

15.High blood pressure

16.Allergic reactions

17.Serious side effects of ketorolac include:

18.Stevens-Johnson syndrome

19.Toxic epidermal necrolysis

20.Anaphylaxis

Other potential side effects of ketorolac include:

1.Confusion

2.Depression

3.Anxiety

4.Ringing in the ears

5.Blurred vision

6.Changes in mood

7.Changes in appetite

8.Weight gain

9.Fatigue

10.Weakness

If you experience any of the serious side effects of ketorolac, stop taking the medication and contact your doctor immediately.

It is important to note that the side effects of ketorolac can be more severe in people with certain medical conditions, such as asthma, kidney disease, liver disease, and heart disease. If you have any of these conditions, talk to your doctor before taking ketorolac.

Ketorolac can also interact with other medications, so it is important to tell your doctor about all of the medications you are taking before you start taking ketorolac.

Overall, ketorolac is a safe and effective medication when used as directed. However, it is important to be aware of the potential side effects and to talk to your doctor before taking it.[30]

How Is Ketorolac Taken?

Ketorolac can be taken orally, in nasal sprays, intravenously, or through intramuscular routes. The Oral version should be administered only as a continuation following IV and IM Ketorolac. Ketorolac tablets and injections should not be taken for more than five days.

Ketorolac has very serious side effects that could be fatal. The increase in dose and length of treatment can increase the risk of side effects like bleeding in the stomach, kidney problems, heart attack and stroke.

How Does Ketorolac Work in the Body?

Like the other NSAIDs, Ketorolac blocks the Cyclooxygenase enzyme (COX 1 and 2). This is required to convert arachidonic acid into prostaglandins resulting in a decrease in pain, fever, and inflammation. The body rapidly absorbs after oral administration with a bioavailability of 80%. After intramuscular administration, Ketorolac reaches maximum plasma concentration in 45 minutes. It is metabolized in the liver and is excreted around 60 % in the urine.

Why Can't One Lie Down After Taking Ketorolac?

It is advised to avoid lying down for about 15 to 30 minutes after taking Ketorolac. This reduces stomach upset and irritation. It can also prevent irritation that may lead to difficulty in swallowing.

What Happens if You Overdose Ketorolac?

Taking an overdose of Ketorolac may exhibit symptoms such as troubled breathing, drowsiness, nausea, and vomiting, which are generally reversible with supportive care. It can cause serious gastrointestinal adverse events including bleeding, ulceration, and perforation, which can be fatal.

Habit-Forming:

Ketorolac is not habit-forming and will not cause physical or mental dependence. It may be used sometimes with a narcotic to provide better pain relief.

What Precautions Should Be Taken Before Administering Ketorolac?

Before administering Ketorolac, it is important to tell your doctor if you have any of the following conditions:

- **Pregnancy and Breastfeeding -** Ketorolac is contraindicated in pregnancy as it may result in low amniotic fluid and risk to the foetus. The medicine passes into breast milk and should be used with caution in lactating women. Ketorolac should be avoided during labour and delivery as it may increase the risk of uterine haemorrhage.
- **Allergies -** Ketorolac is not indicated in individuals who are allergic to other NSAIDs or have had adverse reactions to it.
- **Asthma -** Patients with a history of asthma or worsening breathing after taking NSAIDs should avoid taking Ketorolac as it may lead to anaphylactic reactions.
- **Haemorrhage -** Ketorolac inhibits platelet function and is contraindicated in patients with a high risk of bleeding, suspected cerebrovascular bleeding, and on anticoagulants.



PURIFICATION AND ANALYSIS:

The synthesized ketorolac tromethamine is purified by recrystallization from solvents such as ethanol or isopropanol. The purity and identity of the product are confirmed using various analytical methods, including infrared spectroscopy (IR), nuclear magnetic resonance spectroscopy (NMR), and high-performance liquid chromatography (HPLC). [31]

RESULT:

Ketorolac tromethamine, commonly known as ketorolac, is a potent nonsteroidal anti-inflammatory drug (NSAID) used to treat moderate to severe pain, particularly acute pain, and osteoarthritis. It is available in various formulations, including oral tablets, injectable solutions, and topical gels. Ketorolac is structurally similar to indomethacin, another NSAID, and its synthesis involves a multi-step process. [32]

CONCLUSION:

Ketorolac synthesis is a complex process that involves several steps and requires careful attention to reaction conditions and purification methods. The synthesized product is a potent NSAID with a wide range of therapeutic applications, making it an important pharmaceutical compound. [33]

REFERENCES:

1. Gillis JC, Brogden RN. Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs. 1997 Jan;53(1):139-88.
2. Forrest JB, Heitlinger EL, Revell S. Ketorolac for postoperative pain management in children. Drug Saf. 1997 May;16(5):309-29.
3. Drini M. Peptic ulcer disease and non-steroidal anti-inflammatory drugs. Aust Prescr. 2017 Jun;40(3):91-93.
4. Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. Anesth Analg. 2013 May;116(5):1063-1075.
5. J Clin Pharmacol. 1986 Nov-Dec;26(8):700-5
6. Estenne B, Julien M, Charleux H, Arsac M, Arvis G, et al. Comparison of ketorolac, pentazocine, and placebo in treating postoperative pain. Current Therapeutic Research 43: 1173–1182, 1988
7. Fraser-Smith EB, Matthews TR. Effect of ketorolac on Candida albicans ocular infection in rabbits. Archives of Ophthalmology 105: 264–267, 1987
8. Martinez JJ, Garg DC, Pages LJ, Jallad NS, Yee JP, et al. Single dose pharmacokinetics of ketorolac in healthy young and renal impaired subjects. Abstract. Journal of Clinical Pharmacology 27: 722, 1987
9. Barry B. W. Dermatological Formulations. Marcel Dekker, New York 1983; 49–94
10. Cooper E. R. Increased skin permeability for lipophilic molecules. J. Pharm. Sci. 1984; 73: 153–1156
11. Reinhart D. I. Minimizing the adverse effects of ketorolac. Drug Safety 2000; 22: 487–497
12. Tiwari S. B., Udupa N. Investigation into the potential of iontophoresis facilitated delivery of ketorolac. Int. J. Pharm. 2003; 260: 93–103
13. Yee J. P., Koshiver J. V., Allbon C., Brown C. R. Comparison of intramuscular ketorolac tromethamine and morphine sulfate for analgesia of pain after major surgery. Pharmacotherapy 1986; 6: 253–261

14. Revell S. Ketorolac-induced renal failure. Wis Med J. 1996 Mar;95(3):147.
15. Vacha ME, Huang W, Mando-Vandrick J. The role of subcutaneous ketorolac for pain management. Hosp Pharm. 2015 Feb;50(2):108-12.
16. Drini M. Peptic ulcer disease and non-steroidal anti-inflammatory drugs. Aust Prescr. 2017 Jun;40(3):91-93.
17. Arfè A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, Schink T, Garbe E, Herings R, Straatman H, Schade R, Villa M, Lucchi S, Valkhoff V, Romio S, Thiessard F, Schuemie M, Pariente A, Sturkenboom M, Corrao G., Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28;354:4857.
18. Ingrasciotta Y, Sultana J, Giorgianni F, Fontana A, Santangelo A, Tari DU, Santoro D, Arcoraci V, Perrotta M, Ibanez L, Trifirò G. Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a population-based case control study. PLoS One. 2015;10(4):0122899.

19. Alsarra I.A., Bosela A., Ahmed S., Mahrous G. Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur. J. Pharm. Biopharm. 2005;59:485–490. doi: 10.1016/j.ejpb.2004.09.006.
20. Mamidi N., Castrejón J.V., González-Ortiz A. Rational design and engineering of carbon nano-onions reinforced natural protein nanocomposite hydrogels for biomedical applications. J. Mech. Behav. Biomed. Mater. 2020;104:103696. doi: 10.1016/j.jmbbm.2020.103696.
21. Shih I.-L., Van Y.-T., Shen M.-H. Biomedical applications of chemically and microbiologically synthesized poly (glutamic acid) and poly (lysine) Mini Rev. Med. Chem. 2004;4:179–188. doi: 10.2174/1389557043487420.

22. Vangen O, Doessland S, Lindbaek E. Comparative study of ketorolac and paracetamol/codeine in alleviating pain following gynaecological surgery. Journal of International Medical Research 16: 443–451, 1988

23. Walker JJ, Johnstone J, Lloyd J, Rocha CL. The transfer of ketorolac tromethamine from maternal to foetal blood. European Journal of Clinical Pharmacology 34: 509–511, 1988

24. Wischnik A, Manth SM, Lloyd J, Bullingham R, Thompson JS. The excretion of ketorolac tromethamine into breast milk after multiple oral dosing. European Journal of Clinical Pharmacology 36: 521–524, 1989

25. Sarfraz R., Khan H., Mahmood A., Ahmad M., Maheen S., Sher M. Formulation and evaluation of mouth disintegrating tablets of atenolol and atorvastatin. Indian J. Pharm. Sci. 2015;77:83. doi: 10.4103/0250-474X.151602

26. Zahra Q., Minhas M.U., Khan S., Wu P.-C., Suhail M., Iqbal R., Bashir M. Fabrication of polyethylene glycol hydrogels with enhanced swelling; loading capacity and release kinetics. Polym. Bull. 2021:1–27. doi: 10.1007/s00289-021-03740-8

27. Khalid I., Ahmad M., Minhas M.U., Barkat K. Preparation and characterization of alginate-PVA-based semi-IPN: Controlled release pH-responsive composites. Polym. Bull. 2018;75:1075–1099. doi: 10.1007/s00289-017-2079

28. Sethi P. Quantitative Analysis of Drugs in Pharmaceutical Formulations. 3rd ed. CBS Publications; New Delhi, India: 2008.

29. Peppas N.A., Sahlin J.J. A simple equation for the description of solute release. III. Coupling of diffusion and relaxation. Int. J. Pharm. 1989;57:169–172. doi: 10.1016/0378-5173(89)90306-2

30. Gao Q., Zhang C., Wang M., Wu Y., Gao C., Zhu P. Injectable pH-responsive poly (γ-glutamic acid)-silica hybrid hydrogels with high mechanical strength, conductivity and cytocompatibility for biomedical applications. Polymer. 2020;197:122489. doi: 10.1016/j.polymer.2020.122489

31. Manocha B., Margaritis A. A novel Method for the selective recovery and purification of γ-polyglutamic acid from Bacillus licheniformis fermentation broth. Biotechnol. Prog. 2010;26:734–742. doi: 10.1002/btpr.370

32. Khanum H., Ullah K., Murtaza G., Khan S.A. Fabrication and in vitro characterization of HPMC-g-poly (AMPS) hydrogels loaded with loxoprofen sodium. Int. J. Biol. Macromol. 2018;120:1624–1631. doi: 10.1016/j.ijbiomac.2018.09.184

33. Dasankoppa F.S., Ningangowdar M., Sholapur H. Formulation and evaluation of controlled porosity osmotic pump for oral delivery of ketorolac. J. Basic Clin. Pharm. 2012;4:2. doi: 10.4103/0976-0105.109398